Skip to main content

Table 2 Patient characteristics at baseline

From: Rectum-spacer related acute toxicity – endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers

  Number  
Age (mean) 75 (47–90)
Neoadjuvant hormonal therapy 145 (35.98%)
T stage
 T1a 3 (0.74%)
 T1b 5 (1.24%)
 T1c 186 (46.15%)
 T2 102 (25.31%)
 T2a 15 (3.72%)
 T2b 16 (3.97%)
 T2c 13 (3.23%)
 T3 29 (7.20%)
 T3a 1 (0.25%)
 T3b 5 (1.24%)
 T4 2 (0.50%)
PSA concentration (ng/mL)
 < 10 200 (49.63%)
 10–20 127 (31.51%)
 > 20 68 (16.87%)
Gleason score
 ≤ 6 208 (51.61%)
 7 127 (31.51%)
 ≥ 8 55 (13.65%)
Risk group
 Intermediate 170 (42.18%)
 High 119 (29.53%)
 Low 106 (26.30%)
Nadir 0.53